Predict your next investment

Asset/Investment Management

See what CB Insights has to offer

Investments

177

Portfolio Exits

88

Funds

4

About Cormorant Asset Management

Cormorant Asset Management is a Boston-based investment manager with investment focus in both public and private market innovative companies in the biotechnology and life sciences marketplace.

Cormorant Asset Management Headquarter Location

Boston, Massachusetts,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cormorant Asset Management

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Cormorant Asset Management in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Research containing Cormorant Asset Management

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Cormorant Asset Management in 2 CB Insights research briefs, most recently on Aug 5, 2021.

Latest Cormorant Asset Management News

Tessera raises more than $300 million in Series C financing

Apr 21, 2022

US biotech firm Tessera Therapeutics, which is pioneering a new approach in genetic medicine known as GENE WRITING technology, has raised over $300 million in Series C financing. Investors included a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA); Alaska Permanent Fund Corporation; Altitude Life Science Ventures; ARTIS Ventures; Cormorant Asset Management; Tessera’s founder, Flagship Pioneering; Hanwha Impact Partners; Longevity… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

Cormorant Asset Management Investments

177 Investments

Cormorant Asset Management has made 177 investments. Their latest investment was in MOMA Therapeutics as part of their Series B on May 5, 2022.

CBI Logo

Cormorant Asset Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/10/2022

Series B

MOMA Therapeutics

$150M

No

7

4/29/2022

Series B

Adona Medical

$37.5M

No

2

4/19/2022

Series C

Tessera Therapeutics

$300M

Yes

3

3/1/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

2/16/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/10/2022

4/29/2022

4/19/2022

3/1/2022

2/16/2022

Round

Series B

Series B

Series C

Series C

Series B

Company

MOMA Therapeutics

Adona Medical

Tessera Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$150M

$37.5M

$300M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

2

3

10

10

Cormorant Asset Management Portfolio Exits

88 Portfolio Exits

Cormorant Asset Management has 88 portfolio exits. Their latest portfolio exit was Affinivax on May 31, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/31/2022

Acquired

$99M

6

2/3/2022

Reverse Merger

$99M

3

1/7/2022

IPO

$99M

Public

7

10/21/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/8/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/31/2022

2/3/2022

1/7/2022

10/21/2021

10/8/2021

Exit

Acquired

Reverse Merger

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

6

3

7

10

10

Cormorant Asset Management Fund History

4 Fund Histories

Cormorant Asset Management has 4 funds, including Cormorant Private Healthcare Fund IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

8/4/2021

Cormorant Private Healthcare Fund IV

$253M

1

7/14/2020

Cormorant Private Healthcare Fund III

$99M

10

7/14/2020

Cormorant Private Healthcare Offshore Fund III

$99M

10

Cormorant Private Healthcare Offshore Fund I LP

Subscribe to see more

Subscribe to see more

10

Closing Date

8/4/2021

7/14/2020

7/14/2020

Fund

Cormorant Private Healthcare Fund IV

Cormorant Private Healthcare Fund III

Cormorant Private Healthcare Offshore Fund III

Cormorant Private Healthcare Offshore Fund I LP

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$253M

$99M

$99M

Sources

1

10

10

10

Cormorant Asset Management Team

5 Team Members

Cormorant Asset Management has 5 team members, including current Chief Executive Officer, Managing Director, Bihua Chen.

Name

Work History

Title

Status

Bihua Chen

Putnam Investments

Chief Executive Officer, Managing Director

Current

Jay Scollins

Bain Capital, Sankaty Advisors, and Ernst & Young

Chief Financial Officer, Chief Operating Officer

Current

Raymond J Kelleher

Managing Director

Current

Andrew Phillips

Managing Director

Current

Kelsey Chen

Managing Director

Former

Name

Bihua Chen

Jay Scollins

Raymond J Kelleher

Andrew Phillips

Kelsey Chen

Work History

Putnam Investments

Bain Capital, Sankaty Advisors, and Ernst & Young

Title

Chief Executive Officer, Managing Director

Chief Financial Officer, Chief Operating Officer

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.